Thus, HSPA9/mortalin may also be a potential target to treat anemia in del(5q) MDS patients, although the simultaneous loss of multiple genes on del(5q) likely contributes to the complex phenotypes observed in MDS. This evidence concerns the gene HSPA9 and myelodysplastic syndrome.